Cargando…

Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases

Autoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Henry, Stone, Corey, Murrell, Dédée F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560849/
https://www.ncbi.nlm.nih.gov/pubmed/37818362
http://dx.doi.org/10.3389/fimmu.2023.1243581
_version_ 1785117811476004864
author Tseng, Henry
Stone, Corey
Murrell, Dédée F.
author_facet Tseng, Henry
Stone, Corey
Murrell, Dédée F.
author_sort Tseng, Henry
collection PubMed
description Autoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive cure for AIBDs such as pemphigus, and it continues to have a devastating impact on those affected. The challenges in achieving new approved therapies for AIBDs are complex and multifaceted. One significant obstacle was the prior lack of validated and standardized outcome measures, which are crucial for ensuring precise comparisons between new and traditional therapies. This gap in knowledge has prompted the development of minimal clinically important differences (MCIDs), which enable efficient and reliable comparison of therapeutic outcomes between trials. MCID is defined as the minimum difference in an outcome measure that indicates a clinically significant improvement/deterioration in disease severity. Additionally, MCIDs provide a patient-centered approach to evaluating treatment efficacy, by considering whether patients experience a subjective improvement in their symptoms. Therefore, this literature review will examine the derivation and significance of MCIDs for various scoring systems in AIBDs.
format Online
Article
Text
id pubmed-10560849
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105608492023-10-10 Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases Tseng, Henry Stone, Corey Murrell, Dédée F. Front Immunol Immunology Autoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive cure for AIBDs such as pemphigus, and it continues to have a devastating impact on those affected. The challenges in achieving new approved therapies for AIBDs are complex and multifaceted. One significant obstacle was the prior lack of validated and standardized outcome measures, which are crucial for ensuring precise comparisons between new and traditional therapies. This gap in knowledge has prompted the development of minimal clinically important differences (MCIDs), which enable efficient and reliable comparison of therapeutic outcomes between trials. MCID is defined as the minimum difference in an outcome measure that indicates a clinically significant improvement/deterioration in disease severity. Additionally, MCIDs provide a patient-centered approach to evaluating treatment efficacy, by considering whether patients experience a subjective improvement in their symptoms. Therefore, this literature review will examine the derivation and significance of MCIDs for various scoring systems in AIBDs. Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10560849/ /pubmed/37818362 http://dx.doi.org/10.3389/fimmu.2023.1243581 Text en Copyright © 2023 Tseng, Stone and Murrell https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tseng, Henry
Stone, Corey
Murrell, Dédée F.
Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
title Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
title_full Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
title_fullStr Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
title_full_unstemmed Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
title_short Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
title_sort precision in treatment evaluation: importance of minimal clinically important differences (mcids) of outcome measures for autoimmune blistering diseases
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560849/
https://www.ncbi.nlm.nih.gov/pubmed/37818362
http://dx.doi.org/10.3389/fimmu.2023.1243581
work_keys_str_mv AT tsenghenry precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases
AT stonecorey precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases
AT murrelldedeef precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases